Suzetrigine
chemical compound
Suzetrigine, sold under the brand name Journavx, is an analgesic medication used in the treatment of moderate to severe acute pain. It is taken orally. Suzetrigine was developed by Vertex Pharmaceuticals.
The most common adverse effects include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash.
Suzetrigine is a small-molecule non-opioid analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system. Nav1.8 channels are predominantly present in peripheral nociceptive neurons of the dorsal root ganglia. Suzetrigine inhibits pain signals before they reach the central nervous system and has no addictive potential.
Suzetrigine was approved for medical use in the United States in January 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
Medical uses
Suzetrigine is indicated for the treatment of moderate to severe acute pain in adults.
“Suzetrigine” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Suzetrigine, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Suzetrigine” is worth following because a concise public description often conceals a longer documentary argument. Here, Suzetrigine, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Sep 15, 2026. The linked authority identifier is Q123481189. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2025.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Suzetrigine”, its source revision and the description used here.
- Expand the search: follow Suzetrigine primary sources, Suzetrigine archive and Suzetrigine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Suzetrigine”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Suzetrigine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.